Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 91

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 91
---
 Three Months Ended 
September 30,  
    Nine Months Ended 
September 30, 

    2025  
    2024  
    Variance  
    2025  
    2024  
    Variance 
  
    Cost of Sales 
    $9,491,000  
    $5,169,000  
    $4,322,000  
    $26,406,000  
    $14,406,000  
    $12,000,000 
  
    Gross profit 
    $42,091,000  
    $23,383,000  
    $18,708,000  
    $95,230,000  
    $55,374,000  
    $39,856,000 
  
    Gross margin 
     81.6% 
     81.9% 
     -0.3% 
     78.3% 
     79.4% 
     -1.1%

The
increase in Branded cost of sales was primarily attributable to an increase in units sold during the three and nine months ended September
30, 2025 compared to the prior year periods and an increase in our fixed expenses. The decrease in Branded gross margin between the three
and nine months ended September 30, 2025 and 2024 was primarily attributable to an increase in our fixed expenses, in particular, acquired
product rights amortizations related to the launch of TRIESENCE and a related contingent milestone payment that was capitalized in the
fourth quarter of 2024.

ImprimisRx

    Three Months Ended 
September 30,  
    Nine Months Ended 
September 30, 

    2025  
    2024  
    Variance  
    2025  
    2024  
    Variance 
  
    Cost of Sales 
    $8,221,000  
    $6,849,000  
    $1,372,000  
    $23,060,000  
    $20,704,000  
    $2,356,000 
  
    Gross profit 
    $11,835,000  
    $13,856,000  
    $(2,021,000) 
    $38,515,000  
    $42,299,000  
    $(3